VCP
FOLD

Varenne Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Varenne Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Buy
+180,818
New +$2.59M 0.64% 23

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Varenne Capital Partners's FOLD Position: Q1 2026 in Review

Varenne Capital Partners opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 180,818 shares worth $2.62M. The stake represents 0.64% of the portfolio and ranks #23 among its holdings.

298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Varenne Capital Partners held 180,818 shares of Amicus Therapeutics worth $2.62M as of Q1 2026.
  • Amicus Therapeutics was a new Varenne Capital Partners position in Q1 2026.
  • Amicus Therapeutics made up 0.64% of Varenne Capital Partners's portfolio in Q1 2026, its #23 holding.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Varenne Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.